16 stories mentioning CMPSUpdated 3d ago
Every FINWIRES story that references CMPS, newest first.
COMPASS Pathways (CMPS) has an average rating of buy and mean price target of $22.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
European equities traded in the US as American depositary receipts were lower on Friday morning, shedding 0.6% to 1,899.52 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by energy companies Equinor (EQNR) and Eni (E), which climbed 4.1% and 3.1% respectively.They were followed by biotech companies Genenta Science (GNTA) and DBV Technologies (DBVT), which added 3% and 2.2%.The decliners from continental Europe were led by tech company Nokia (NOK), which dropped 3%, and semiconductor companies STMicroelectronics (STM) and ASML (ASML), which fell 2.6% each.They were followed by software company SAP (SAP), which shed 1.8%.From the UK and Ireland, the gainers were led by pharmaceutical company Compass Pathways (CMPS), which climbed 4.8%, and energy companies Shell (SHEL) and BP (BP), which added 2.3% and 1.4% respectively.The decliners from the UK and Ireland were led by budget airline Ryanair (RYAAY) and pharmaceutical company GSK (GSK), which lost 3.6% and 2.8% respectively. They were followed by bank Barclays (BCS), which shed 2.1%.
European equities traded in the US as American depositary receipts were slightly lower on Thursday morning, down 0.07% to 1,911.26 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by pharmaceutical company Novo Nordisk (NVO) and drink and brewing company Anheuser-Busch Inbev (BUD), which rose 1.9% and 0.9% respectivelyThey were followed by pharmaceutical company Novartis (NVS), which added 0.8%.The decliners from continental Europe were led by tech companies Nokia (NOK) and Ericsson (ERIC), which fell 7.8% and 1.8% respectively.They were followed by bank Santander (SAN), which shed 1.5%.From the UK and Ireland, the gainers were led by advertising and PR agency WPP (WPP) and telecom giant Vodafone (VOD), which rose 3.8% and 3% respectively. They were followed by beverage company Diageo (DEO), which added 2.5%.The decliners from the UK and Ireland were led by semiconductor company Arm (ARM) and pharmaceutical company Compass Pathways (CMPS), which lost 6.9% and 2.1% respectively.
European equities traded in the US as American depositary receipts were rising on Thursday morning, up 0.5% to 1,905.06 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by technology giants Nokia (NOK) and Ericsson (ERIC), which gained 6% and 4.4% respectively. They were followed by semiconductor company STMicroelectronics (STM), which climbed nearly 4%.The decliners from continental Europe were led by clinical-stage biopharmaceutical company Inventiva (IVA) and steel producer ArcelorMittal (MT), which fell 4.3% and 1.5% respectively. They were followed by software company SAP (SAP), which shed 0.7%.From the UK and Ireland, the gainers were led by semiconductor company Arm (ARM) and bank HSBC (HSBC), which climbed 12% and 2% respectively. They were followed by bank Barclays (BCS), which added 1.8%.The decliners from the UK and Ireland were led by pharmaceutical company Compass Pathways (CMPS) and budget airline Ryanair (RYAAY), which decreased 2.2% and 1.5% respectively.
Compass Pathways' (CMPS) recent six-month trial data for COMP360 in treatment-resistant depression supports its potential for US Food and Drug Administration approval, a 2027 launch, and a more than $1.7 billion market opportunity, RBC Capital Markets said in a note Tuesday.The analysts said the data showed a meaningful dose-response, durability, and a more convenient dosing schedule than currently marketed alternatives.The treatment also continued to show a favorable safety profile, with most adverse events occurring only on the day of treatment, according to RBC.Given the strong clinical data, favorable regulatory designations, physician interest and patient demand, Compass Pathways is well positioned for future share price gains driven by its underlying business fundamentals, the analysts said.They added that COMP360's effectiveness is competitive with newer treatments such as Spravato and LSD-based therapies, offering durable benefits after one to three doses, "and when accounting for differing populations, we also think the efficacy is in the ballpark of other psychedelics."RBC has an outperform rating and a $22 price target on Compass Pathways.Price: $13.25, Change: $+0.25, Percent Change: +1.96%
European equities traded in the US as American depositary receipts were lower Friday morning, decreasing 0.4% to 1,883.22 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech companies Evaxion (EVAX) and Abivax (ABVX), which gained 5.4% and 4.5% respectively. They were followed by healthcare firm Grifols (GRFS) and drink and brewing giant Anheuser-Busch Inbev (BUD), which added 1.4% and 1.1%, respectively.The decliners from continental Europe were led by Agomab Therapeutics (AGMB) and steel producer ArcelorMittal (MT), which fell 3.9% and 3.5% respectively. They were followed by energy company Equinor (EQNR), which was down 1.3%.From the UK and Ireland, the gainers were led by pharmaceutical company Compass Pathways (CMPS) and Autolus Therapeutics (AUTL), which rose 5.6% and 2.8% respectively.The decliners from the UK and Ireland were led by semiconductor company Arm (ARM) and Barclays (BCS), which shed 4% and 1.3% respectively.
COMPASS Pathways (CMPS) has an average rating of Buy and mean price target of $20.97, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index down 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.4%.The iShares Biotechnology ETF (IBB) fell 1%.In sector news, the US Food and Drug Administration said it was launching regulatory actions to back the development of psychedelic therapies to treat mental illness. The move builds on President Donald Trump's recent executive order directing the Department of Health and Human Services to accelerate access to treatments for people with serious mental illness, the FDA said.In corporate news, HCA Healthcare's (HCA) Q1 results exceeded market expectations, but the hospital operator said it did not see its usual seasonal lift in admissions amid declines in respiratory activity. Its shares dropped 9%.Organon (OGN) shares surged 32% amid a report that India's Sun Pharmaceutical Industries was planning a $13 billion bid for the company.Compass Pathways (CMPS) shares rose 4.8% after it said Friday the US Food and Drug Administration has granted its rolling review request for its new drug application and selected COMP360 for the Commissioner's National Priority Voucher program for treatment-resistant depression.Sanofi (SNY) priced a 2.3 billion euro ($2.7 billion) offering of notes under its Euro Medium Term Note program. Its shares were down 1.5%.
Health care stocks were lower Friday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 1.4%.The iShares Biotechnology ETF (IBB) decreased 0.7%.In sector news, the US Food and Drug Administration said it was launching regulatory actions to back the development of psychedelic therapies to treat mental illness. The move builds on President Donald Trump's recent executive order directing the Department of Health and Human Services to accelerate access to treatments for people with serious mental illness, the FDA said.In corporate news, HCA Healthcare's (HCA) Q1 results exceeded market expectations, but the hospital operator said it did not see its usual seasonal lift in admissions amid declines in respiratory activity. Its shares dropped 9%.Organon (OGN) shares surged 28% amid a report that India's Sun Pharmaceutical Industries was planning a $13 billion bid for the company.Compass Pathways (CMPS) shares rose 5% after it said Friday the US Food and Drug Administration has granted its rolling review request for its new drug application and selected COMP360 for the Commissioner's National Priority Voucher program for treatment-resistant depression.
Compass Pathways (CMPS) said Friday the US Food and Drug Administration has granted its rolling review request for its new drug application and selected COMP360 for the Commissioner's National Priority Voucher program for treatment-resistant depression.Companies selected for the program are eligible for benefits including enhanced communications and a shortened 1-2 month review time, the company said.Price: $9.17, Change: $+0.02, Percent Change: +0.22%
Shares of some psychedelic drug companies gained Friday morning after the US Food and Drug Administration said it was launching regulatory actions to back the development of psychedelic therapies to treat mental illness.Cybin (HELP) shares jumped past 4%, Psyence Biomedical (PBM) shares climbed 7%, and Clearmind Medicine (CMND) shares were up 2.4%.The FDA's move builds on President Donald Trump's recent executive order directing the Department of Health and Human Services to accelerate access to treatments for people with serious mental illness, the FDA said.The drugs have the potential to address mental health diseases like treatment-resistant depression, alcoholism and substance abuse, said FDA Commissioner Marty Makary.The agency said it is issuing national priority vouchers to three companies researching psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for post-traumatic stress disorder.The agency said it is also allowing an early-phase trial of noribogaine hydrochloride to proceed following an investigational new drug filing. The sponsor is investigating noribogaine to potentially treat alcohol use disorder, the FDA said, adding the move will allow the company developing the new drug, DemeRx NB, to start a phase 1 trial in the US.The agency said it will release final guidance "imminently" to provide recommendations to sponsors developing psychedelic medications.Price: $8.89, Change: $-0.27, Percent Change: -2.90%
COMPASS Pathways (CMPS) has an average rating of buy and mean price target of $22.08, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1%.The iShares Biotechnology ETF (IBB) decreased 0.4%.In corporate news, Tvardi Therapeutics (TVRD) shares fell 4.1% after Barclays downgraded the company's stock to underweight from equalweight and adjusted the price target to $3 from $4.Eli Lilly (LLY) has agreed to buy clinical-stage biotechnology firm Kelonia Therapeutics for up to $7 billion, as the drugmaker looks to bolster its cancer treatment portfolio. Lilly shares were easing 0.6%.Compass Pathways (CMPS), GH Research (GHRS), and other psychedelic companies' shares were up on Monday, after US President Donald Trump signed an executive order Saturday to expedite access to treatments for patients with serious mental illness. Compass shares surged 42%, and GH Research jumped 17%.Nektar Therapeutics (NKTR) shares climbed 18% after it said Monday that data from a 16-week extension period of its phase 2b study of rezpegaldesleukin showed a "deepening of response" in people with severe-to-very-severe alopecia areata.
Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.5%.The iShares Biotechnology ETF (IBB) was down 0.2%.In corporate news, Eli Lilly (LLY) has agreed to buy clinical-stage biotechnology firm Kelonia Therapeutics for up to $7 billion, as the drugmaker looks to bolster its cancer treatment portfolio. Lilly shares were easing 0.1%.Compass Pathways (CMPS), GH Research (GHRS), and other psychedelic companies' shares were up on Monday, after US President Donald Trump signed an executive order Saturday to expedite access to treatments for patients with serious mental illness. Compass shares surged 47%, and GH Research jumped 15%.Nektar Therapeutics (NKTR) shares climbed 22% after it said Monday that data from a 16-week extension period of its phase 2b study of rezpegaldesleukin showed a "deepening of response" in people with severe-to-very-severe alopecia areata.
Nektar Therapeutics (NKTR) said Monday that data from a 16-week extension period of its phase 2b study of rezpegaldesleukin showed a "deepening of response" in patients with severe-to-very-severe alopecia areata.Wedbush Securities lifted its price target for Nektar Therapeutics' shares to $95 from $70 while maintaining the stock's neutral rating.Shares of Nektar jumped 22%, with intraday trading volume of nearly 3.4 million, up from a daily average of about 1.1 million.Compass Pathways (CMPS), GH Research (GHRS), and other psychedelic companies' shares were up on Monday, after US President Donald Trump signed an executive order Saturday to expedite access to treatments for patients with serious mental illness.Shares of Compass Pathways surged 49% as intraday trading volume soared to over 29 million from a daily average of about 3.05 million.GH Research shares advanced 14% as intraday trading volume jumped to over 953,700 from a daily average of roughly 192,000.Price: $103.50, Change: $+18.64, Percent Change: +21.97%
Theriva Biologics (TOVX) shares were up 94% in Monday premarket activity, adding to Friday's gain.Compass Pathways (CMPS) stock was 25% higher after the company said over the weekend it commended the White House executive order to accelerate research and access for psychedelic treatments.TopBuild (BLD) shares were up 19%, a day after QXO (QXO) said it agreed to acquire TopBuild for $505 per share in a deal valued at about $17 billion.Marvell Technology (MRVL) stock was 6.3% higher after The Information reported Sunday that Alphabet's (GOOG, GOOGL) Google is negotiating with Marvell to develop two new processors optimized for artificial intelligence inference tasks.Eni (E) shares were up 2% after the company said it has made gas discovery in the Kutei Basin off the coast of Indonesia.
